ORT-VAC: live bacterial vectors for vaccine delivery

ORT-VAC：用于疫苗递送的活细菌载体

• 批准号: DT/F002343/1
• 负责人: Nigel Slater
• 金额: $ 36.01万
• 依托单位: University of Cambridge
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2008
• 资助国家: 英国
• 起止时间: 2008 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=DT%2FF002343%2F1
• 关键词: ORT; VAC; live; bacterial; vectors

We aim to revolutionise vaccination by developing an innovative oral vaccine delivery technology. Traditional vaccines require extensive and costly production, purification, formulation and storage, with needles used for administration. We will engineer live enteric ORT-VAC bacteria to carry plasmids expressing antigens. These uniquely enable stable, high-copy number plasmid maintenance without antibiotic resistance or other selectable marker genes, making them particularly suited for delivering DNA vaccines against influenza and HIV, which will also be developed by the consortium. Encapsulation technology will be optimised to enable the bacteria to be stored at ambient temperature, ingested and released into the small intestine, where they will stimulate a protective immune response. ORT-VAC therefore represents a cost-effective platform technology with built-in stability, adjuvanticity and efficacy.

我们的目标是通过开发创新的口服疫苗输送技术来彻底改变疫苗接种。传统疫苗需要大量且昂贵的生产、纯化、配制和储存，并使用针头进行接种。我们将设计活的肠道ORT-VAC细菌携带表达抗原的质粒。这些独特的使稳定的，高拷贝数的质粒维持没有抗生素抗性或其他选择标记基因，使它们特别适合于提供针对流感和HIV的DNA疫苗，这也将由该财团开发。封装技术将得到优化，使细菌能够在环境温度下储存，摄入并释放到小肠中，在那里它们将刺激保护性免疫反应。因此，ORT-VAC代表了一种具有成本效益的平台技术，具有内置的稳定性，佐剂性和功效。

项目成果

A novel formulation for oral delivery of live bacterial vaccines

一种口服活细菌疫苗的新配方

• 发表时间: 2010
• 作者: Alexander Edwards